6 results  1 of 1 

1 Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008–2016
Hyemin Yi, Ji-Ho Lee, Ju-Young Shin
Yonsei Med J.2019;60(2):200-207.   Published online 2019 January 17     DOI: http://dx.doi.org/10.3349/ymj.2019.60.2.200
      
2 Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice
Gwon-Soo Jung, Jae-Han Jeon, Mi Sun Choe, Sung-Woo Kim, In-Kyu Lee, Mi-Kyung Kim, Keun-Gyu Park
Diabetes Metab J.2016;40(3):211-221.   Published online 2016 March 31     DOI: http://dx.doi.org/10.4093/dmj.2016.40.3.211
      
3 Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
Endocrinol Metab.2015;30(1):84-91.   Published online 2015 March 27     DOI: http://dx.doi.org/10.3803/EnM.2015.30.1.84
      
4 The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
Eun Yeong Choe, Yongin Cho, Younjeong Choi, Yujung Yun, Hye Jin Wang, Obin Kwon, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Eun Seok Kang
Diabetes Metab J.2014;38(3):211-219.   Published online 2014 June 17     DOI: http://dx.doi.org/10.4093/dmj.2014.38.3.211
      
5 Incretin-based Combination Therapy in Type 2 Diabetes Mellitus
Jae Hyeon Kim, Myung-Shik Lee
J Korean Med Assoc.2009;52(10):1030-1036.   Published online 2009 October 31     DOI: http://dx.doi.org/10.5124/jkma.2009.52.10.1030
      
6 DPP-4 Inhibitors and the Relations between Rosiglitazone and the Risk of Myocardial Infarction
Hyoung Woo Lee
J Korean Med Assoc.2008;51(4):371-376.   Published online 2008 April 30     DOI: http://dx.doi.org/10.5124/jkma.2008.51.4.371
      

 1 of 1